Luisa Mestroni
Concepts (614)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiomyopathy, Dilated | 106 | 2026 | 356 | 12.780 |
Why?
| | Cardiomyopathies | 39 | 2025 | 335 | 6.400 |
Why?
| | Arrhythmogenic Right Ventricular Dysplasia | 26 | 2026 | 60 | 5.810 |
Why?
| | Arrhythmias, Cardiac | 37 | 2026 | 355 | 4.940 |
Why?
| | Myocytes, Cardiac | 32 | 2026 | 546 | 3.990 |
Why?
| | Death, Sudden, Cardiac | 22 | 2025 | 232 | 2.960 |
Why?
| | Heart Failure | 38 | 2026 | 2326 | 2.590 |
Why?
| | Filamins | 9 | 2025 | 28 | 2.520 |
Why?
| | Nanotubes, Carbon | 7 | 2025 | 46 | 2.410 |
Why?
| | Lamin Type A | 19 | 2025 | 49 | 2.410 |
Why?
| | Cardiomyopathy, Hypertrophic | 17 | 2025 | 143 | 2.280 |
Why?
| | Phenotype | 41 | 2026 | 3155 | 2.120 |
Why?
| | Tissue Engineering | 8 | 2025 | 439 | 2.060 |
Why?
| | Myocardium | 27 | 2026 | 934 | 1.980 |
Why?
| | Mutation | 42 | 2026 | 4075 | 1.870 |
Why?
| | Genetic Predisposition to Disease | 29 | 2026 | 2378 | 1.590 |
Why?
| | Precision Medicine | 7 | 2026 | 459 | 1.590 |
Why?
| | Ventricular Remodeling | 11 | 2026 | 278 | 1.440 |
Why?
| | Muscle Proteins | 8 | 2025 | 242 | 1.340 |
Why?
| | Connectin | 14 | 2026 | 42 | 1.270 |
Why?
| | Electrocardiography | 18 | 2025 | 665 | 1.250 |
Why?
| | Genetic Testing | 16 | 2025 | 480 | 1.200 |
Why?
| | Induced Pluripotent Stem Cells | 7 | 2025 | 273 | 1.170 |
Why?
| | Fibroblasts | 8 | 2026 | 1025 | 1.150 |
Why?
| | Heart | 11 | 2025 | 626 | 1.150 |
Why?
| | Ventricular Function, Left | 14 | 2025 | 542 | 1.150 |
Why?
| | Genetic Variation | 6 | 2021 | 972 | 1.110 |
Why?
| | Tissue Scaffolds | 6 | 2022 | 221 | 1.100 |
Why?
| | Humans | 220 | 2026 | 145474 | 1.050 |
Why?
| | Valsartan | 6 | 2025 | 32 | 1.030 |
Why?
| | Glycogen Storage Disease Type IIb | 8 | 2025 | 27 | 0.990 |
Why?
| | Cell Adhesion | 11 | 2021 | 451 | 0.990 |
Why?
| | Hydrogels | 3 | 2025 | 701 | 0.970 |
Why?
| | Desmoplakins | 5 | 2025 | 24 | 0.950 |
Why?
| | Sarcomeres | 7 | 2024 | 97 | 0.930 |
Why?
| | Prognosis | 28 | 2025 | 4316 | 0.920 |
Why?
| | Heart Ventricles | 14 | 2025 | 756 | 0.890 |
Why?
| | Stroke Volume | 19 | 2025 | 654 | 0.800 |
Why?
| | Pharmacogenetics | 5 | 2014 | 175 | 0.790 |
Why?
| | Amyloid Neuropathies, Familial | 1 | 2023 | 26 | 0.790 |
Why?
| | Ventricular Dysfunction, Left | 9 | 2025 | 394 | 0.790 |
Why?
| | Mutation, Missense | 9 | 2021 | 335 | 0.720 |
Why?
| | Pedigree | 29 | 2021 | 515 | 0.700 |
Why?
| | Middle Aged | 75 | 2026 | 36215 | 0.700 |
Why?
| | Biocompatible Materials | 2 | 2025 | 429 | 0.690 |
Why?
| | Gold | 3 | 2020 | 116 | 0.690 |
Why?
| | Registries | 18 | 2026 | 2406 | 0.680 |
Why?
| | Male | 111 | 2026 | 72842 | 0.680 |
Why?
| | Risk Assessment | 16 | 2025 | 3747 | 0.670 |
Why?
| | Adult | 80 | 2026 | 40777 | 0.660 |
Why?
| | Microscopy, Atomic Force | 11 | 2022 | 128 | 0.660 |
Why?
| | Female | 107 | 2026 | 78844 | 0.620 |
Why?
| | Genetic Therapy | 2 | 2017 | 316 | 0.590 |
Why?
| | Metal Nanoparticles | 2 | 2020 | 80 | 0.590 |
Why?
| | Hypertrophy, Left Ventricular | 4 | 2025 | 124 | 0.560 |
Why?
| | Clinical Trials, Phase II as Topic | 2 | 2022 | 75 | 0.550 |
Why?
| | Dystrophin | 10 | 2020 | 41 | 0.530 |
Why?
| | Plakophilins | 4 | 2023 | 5 | 0.530 |
Why?
| | Ventricular Function | 1 | 2017 | 53 | 0.520 |
Why?
| | Echocardiography | 13 | 2025 | 647 | 0.510 |
Why?
| | Animals | 43 | 2026 | 38030 | 0.510 |
Why?
| | Heterozygote | 10 | 2025 | 313 | 0.500 |
Why?
| | Isolated Noncompaction of the Ventricular Myocardium | 1 | 2016 | 4 | 0.500 |
Why?
| | Rho Guanine Nucleotide Exchange Factors | 1 | 2016 | 27 | 0.500 |
Why?
| | Rats | 14 | 2026 | 5584 | 0.480 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 4 | 2025 | 38 | 0.480 |
Why?
| | Laminin | 1 | 2016 | 72 | 0.470 |
Why?
| | Protein Kinases | 4 | 2013 | 312 | 0.470 |
Why?
| | Biomimetics | 1 | 2016 | 41 | 0.470 |
Why?
| | Magnetic Resonance Imaging, Cine | 4 | 2025 | 214 | 0.460 |
Why?
| | Fibrosis | 6 | 2026 | 559 | 0.460 |
Why?
| | Myocardial Infarction | 3 | 2026 | 1210 | 0.450 |
Why?
| | Gene Expression Regulation | 5 | 2026 | 2597 | 0.450 |
Why?
| | Embryonic Stem Cells | 1 | 2016 | 124 | 0.450 |
Why?
| | Cell Adhesion Molecules | 2 | 2023 | 181 | 0.440 |
Why?
| | DNA Mutational Analysis | 11 | 2018 | 407 | 0.440 |
Why?
| | Multicenter Studies as Topic | 1 | 2017 | 412 | 0.440 |
Why?
| | Myocarditis | 6 | 2025 | 102 | 0.440 |
Why?
| | Defibrillators, Implantable | 4 | 2021 | 382 | 0.440 |
Why?
| | Polymers | 4 | 2022 | 485 | 0.440 |
Why?
| | Genetic Heterogeneity | 2 | 2009 | 66 | 0.430 |
Why?
| | Receptors, Endothelin | 2 | 2014 | 48 | 0.430 |
Why?
| | Receptors, Adrenergic | 1 | 2014 | 20 | 0.420 |
Why?
| | Cardiovascular Agents | 2 | 2025 | 166 | 0.420 |
Why?
| | Materials Testing | 3 | 2025 | 345 | 0.420 |
Why?
| | Myofibroblasts | 3 | 2026 | 148 | 0.410 |
Why?
| | Ventricular Dysfunction, Right | 4 | 2023 | 248 | 0.410 |
Why?
| | Risk Factors | 19 | 2026 | 10885 | 0.410 |
Why?
| | Tachycardia, Ventricular | 5 | 2024 | 180 | 0.410 |
Why?
| | Genetic Association Studies | 6 | 2025 | 369 | 0.410 |
Why?
| | Connexin 43 | 1 | 2014 | 36 | 0.400 |
Why?
| | Lysine | 1 | 2016 | 305 | 0.400 |
Why?
| | src-Family Kinases | 1 | 2014 | 92 | 0.390 |
Why?
| | Disease Progression | 7 | 2025 | 2864 | 0.390 |
Why?
| | Ectodermal Dysplasia | 2 | 2025 | 20 | 0.380 |
Why?
| | Genes, Dominant | 12 | 2007 | 100 | 0.370 |
Why?
| | Cytoskeleton | 7 | 2020 | 192 | 0.370 |
Why?
| | Cardiac Resynchronization Therapy | 2 | 2024 | 63 | 0.370 |
Why?
| | Extracellular Matrix | 4 | 2025 | 562 | 0.360 |
Why?
| | Genotype | 9 | 2025 | 1852 | 0.350 |
Why?
| | Retrospective Studies | 24 | 2026 | 17291 | 0.340 |
Why?
| | Human Genome Project | 1 | 2011 | 15 | 0.340 |
Why?
| | Disease Management | 4 | 2021 | 653 | 0.340 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1747 | 0.340 |
Why?
| | Mechanotransduction, Cellular | 2 | 2025 | 121 | 0.330 |
Why?
| | Genome, Human | 2 | 2025 | 420 | 0.330 |
Why?
| | RNA-Binding Proteins | 3 | 2026 | 447 | 0.330 |
Why?
| | Cells, Cultured | 10 | 2026 | 4148 | 0.320 |
Why?
| | Electrocardiography, Ambulatory | 4 | 2025 | 63 | 0.320 |
Why?
| | Nuclear Proteins | 2 | 2009 | 740 | 0.310 |
Why?
| | Genetic Linkage | 10 | 2001 | 272 | 0.310 |
Why?
| | Particle Size | 2 | 2025 | 381 | 0.290 |
Why?
| | Cell Differentiation | 2 | 2017 | 2046 | 0.290 |
Why?
| | Muscular Dystrophies | 2 | 2018 | 28 | 0.290 |
Why?
| | Ethylenediamines | 3 | 2023 | 7 | 0.280 |
Why?
| | Italy | 13 | 2020 | 116 | 0.280 |
Why?
| | Molecular Biology | 4 | 1997 | 58 | 0.280 |
Why?
| | Desmosomes | 3 | 2019 | 22 | 0.280 |
Why?
| | Chromosome Mapping | 8 | 1997 | 506 | 0.280 |
Why?
| | Indazoles | 3 | 2023 | 85 | 0.270 |
Why?
| | Double-Blind Method | 6 | 2025 | 2062 | 0.260 |
Why?
| | Lamins | 2 | 2004 | 4 | 0.260 |
Why?
| | Myosin Heavy Chains | 3 | 2013 | 183 | 0.260 |
Why?
| | Adolescent | 30 | 2026 | 22529 | 0.260 |
Why?
| | Heart Rate | 3 | 2025 | 855 | 0.250 |
Why?
| | DNA Methylation | 2 | 2025 | 674 | 0.250 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2020 | 534 | 0.250 |
Why?
| | Heart Transplantation | 8 | 2025 | 680 | 0.250 |
Why?
| | Proteomics | 2 | 2025 | 1188 | 0.250 |
Why?
| | Mice | 15 | 2026 | 18329 | 0.250 |
Why?
| | Rats, Sprague-Dawley | 4 | 2026 | 2524 | 0.240 |
Why?
| | RNA Splicing | 2 | 2026 | 284 | 0.240 |
Why?
| | Immunosuppressive Agents | 3 | 2025 | 838 | 0.240 |
Why?
| | Repressor Proteins | 1 | 2009 | 429 | 0.230 |
Why?
| | Iodide Peroxidase | 1 | 2026 | 35 | 0.230 |
Why?
| | Gene Expression Profiling | 2 | 2026 | 1767 | 0.230 |
Why?
| | Aged | 32 | 2026 | 26153 | 0.230 |
Why?
| | Genetic Diseases, Inborn | 1 | 2025 | 45 | 0.220 |
Why?
| | Failure to Thrive | 1 | 2025 | 28 | 0.220 |
Why?
| | Ventricular Myosins | 1 | 2005 | 39 | 0.220 |
Why?
| | Animals, Newborn | 5 | 2022 | 891 | 0.220 |
Why?
| | Chromosomes, Human, Y | 1 | 2025 | 37 | 0.220 |
Why?
| | Rare Diseases | 1 | 2025 | 116 | 0.210 |
Why?
| | Follow-Up Studies | 17 | 2025 | 5423 | 0.210 |
Why?
| | Injections | 1 | 2025 | 199 | 0.210 |
Why?
| | Exercise Test | 5 | 2024 | 630 | 0.210 |
Why?
| | Muscular Dystrophy, Emery-Dreifuss | 1 | 2023 | 3 | 0.210 |
Why?
| | Time Factors | 12 | 2025 | 7123 | 0.210 |
Why?
| | Quantitative Trait Loci | 1 | 2026 | 378 | 0.200 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2004 | 15 | 0.200 |
Why?
| | Young Adult | 15 | 2026 | 14218 | 0.200 |
Why?
| | Desmin | 2 | 2018 | 24 | 0.200 |
Why?
| | Rheology | 1 | 2024 | 94 | 0.200 |
Why?
| | Syncope | 1 | 2024 | 56 | 0.200 |
Why?
| | Tachycardia | 1 | 2023 | 57 | 0.200 |
Why?
| | X Chromosome | 8 | 2001 | 65 | 0.200 |
Why?
| | Prealbumin | 1 | 2023 | 37 | 0.200 |
Why?
| | Alternative Splicing | 1 | 2026 | 247 | 0.200 |
Why?
| | Spheroids, Cellular | 1 | 2024 | 74 | 0.200 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 2121 | 0.190 |
Why?
| | NAD | 1 | 2023 | 79 | 0.190 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2026 | 196 | 0.190 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2004 | 592 | 0.190 |
Why?
| | Genetic Markers | 4 | 2018 | 335 | 0.190 |
Why?
| | AMP-Activated Protein Kinases | 2 | 2016 | 192 | 0.190 |
Why?
| | High-Throughput Nucleotide Sequencing | 5 | 2025 | 530 | 0.190 |
Why?
| | Progeria | 1 | 2022 | 6 | 0.190 |
Why?
| | Point Mutation | 4 | 2011 | 240 | 0.190 |
Why?
| | Ventricular Function, Right | 2 | 2023 | 297 | 0.180 |
Why?
| | Myocardial Contraction | 4 | 2023 | 293 | 0.180 |
Why?
| | Exercise Tolerance | 1 | 2024 | 283 | 0.180 |
Why?
| | Sex Characteristics | 2 | 2025 | 782 | 0.180 |
Why?
| | Temperature | 1 | 2025 | 633 | 0.180 |
Why?
| | Nerve Tissue Proteins | 1 | 2026 | 591 | 0.180 |
Why?
| | Chromosomes, Human, Pair 9 | 3 | 1997 | 36 | 0.180 |
Why?
| | Aortic Valve Stenosis | 1 | 2025 | 256 | 0.180 |
Why?
| | Aortic Valve | 1 | 2025 | 364 | 0.170 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2022 | 53 | 0.170 |
Why?
| | Microtechnology | 1 | 2021 | 8 | 0.170 |
Why?
| | Chagas Cardiomyopathy | 1 | 2021 | 27 | 0.170 |
Why?
| | Chagas Disease | 1 | 2021 | 42 | 0.170 |
Why?
| | Heart Murmurs | 1 | 2021 | 14 | 0.170 |
Why?
| | Adrenergic beta-Antagonists | 4 | 2025 | 252 | 0.170 |
Why?
| | ADAM10 Protein | 1 | 2021 | 29 | 0.170 |
Why?
| | Actinin | 1 | 2020 | 12 | 0.160 |
Why?
| | Gamma Rays | 1 | 2021 | 57 | 0.160 |
Why?
| | Mechanical Phenomena | 1 | 2021 | 80 | 0.160 |
Why?
| | Atrial Fibrillation | 2 | 2025 | 558 | 0.160 |
Why?
| | NAV1.5 Voltage-Gated Sodium Channel | 3 | 2017 | 16 | 0.160 |
Why?
| | Combined Modality Therapy | 2 | 2021 | 1266 | 0.160 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 78 | 0.160 |
Why?
| | Heart Diseases | 1 | 2023 | 341 | 0.160 |
Why?
| | Genomics | 2 | 2017 | 825 | 0.160 |
Why?
| | Epidermolysis Bullosa Simplex | 1 | 2020 | 14 | 0.160 |
Why?
| | Treatment Outcome | 11 | 2025 | 11772 | 0.160 |
Why?
| | Heart Conduction System | 3 | 2016 | 96 | 0.160 |
Why?
| | Elastic Modulus | 5 | 2022 | 121 | 0.150 |
Why?
| | Neuromuscular Diseases | 1 | 2002 | 145 | 0.150 |
Why?
| | Cell Proliferation | 5 | 2025 | 2507 | 0.150 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2021 | 93 | 0.150 |
Why?
| | Nanotechnology | 1 | 2020 | 114 | 0.150 |
Why?
| | Elasticity | 2 | 2017 | 189 | 0.150 |
Why?
| | Heart-Assist Devices | 1 | 2026 | 568 | 0.150 |
Why?
| | Ankyrins | 1 | 2019 | 11 | 0.150 |
Why?
| | Radiation Injuries | 1 | 2021 | 149 | 0.150 |
Why?
| | Nanostructures | 1 | 2020 | 105 | 0.150 |
Why?
| | Muscular Diseases | 1 | 2000 | 108 | 0.150 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2021 | 218 | 0.150 |
Why?
| | Gene Deletion | 2 | 1997 | 391 | 0.150 |
Why?
| | Cohort Studies | 9 | 2026 | 6013 | 0.140 |
Why?
| | Child | 19 | 2026 | 22707 | 0.140 |
Why?
| | Biopsy | 4 | 2022 | 1082 | 0.140 |
Why?
| | Immunity, Cellular | 2 | 2018 | 274 | 0.140 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 219 | 0.140 |
Why?
| | Actin Cytoskeleton | 2 | 2021 | 103 | 0.140 |
Why?
| | Down Syndrome | 1 | 2025 | 525 | 0.140 |
Why?
| | Membrane Proteins | 2 | 2021 | 1164 | 0.140 |
Why?
| | Cytochalasin D | 2 | 2015 | 4 | 0.140 |
Why?
| | Coculture Techniques | 1 | 2019 | 247 | 0.140 |
Why?
| | DNA | 2 | 2016 | 1435 | 0.140 |
Why?
| | Alleles | 1 | 2021 | 894 | 0.140 |
Why?
| | Cell Nucleus | 3 | 2019 | 588 | 0.140 |
Why?
| | Sodium Channels | 2 | 2011 | 63 | 0.140 |
Why?
| | Intermediate Filaments | 1 | 2017 | 25 | 0.130 |
Why?
| | Skin Physiological Phenomena | 1 | 2017 | 24 | 0.130 |
Why?
| | Sequence Analysis, DNA | 3 | 2025 | 777 | 0.130 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2025 | 425 | 0.130 |
Why?
| | Family Health | 2 | 2011 | 191 | 0.130 |
Why?
| | Cardiac Imaging Techniques | 1 | 2017 | 24 | 0.130 |
Why?
| | Contrast Media | 1 | 2021 | 497 | 0.130 |
Why?
| | Ion Channels | 1 | 2018 | 129 | 0.130 |
Why?
| | Wnt Signaling Pathway | 1 | 2019 | 211 | 0.130 |
Why?
| | Gelatin | 1 | 2017 | 56 | 0.130 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2021 | 293 | 0.130 |
Why?
| | Age of Onset | 3 | 2026 | 555 | 0.130 |
Why?
| | Heart Defects, Congenital | 1 | 2025 | 910 | 0.120 |
Why?
| | Vasodilator Agents | 4 | 1988 | 330 | 0.120 |
Why?
| | Internationality | 1 | 2017 | 156 | 0.120 |
Why?
| | Odds Ratio | 2 | 2017 | 1082 | 0.120 |
Why?
| | Myocardial Ischemia | 1 | 2018 | 285 | 0.120 |
Why?
| | Biomechanical Phenomena | 4 | 2024 | 857 | 0.120 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2017 | 103 | 0.120 |
Why?
| | MicroRNAs | 2 | 2020 | 686 | 0.120 |
Why?
| | Troponin T | 2 | 2013 | 63 | 0.120 |
Why?
| | Muscle, Skeletal | 6 | 2005 | 1789 | 0.120 |
Why?
| | Multigene Family | 1 | 2017 | 210 | 0.120 |
Why?
| | Keratinocytes | 1 | 2017 | 249 | 0.120 |
Why?
| | Exome | 2 | 2017 | 227 | 0.120 |
Why?
| | Shear Strength | 1 | 2016 | 73 | 0.120 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1547 | 0.120 |
Why?
| | Transcriptome | 2 | 2020 | 1038 | 0.120 |
Why?
| | Prevalence | 8 | 2021 | 2865 | 0.120 |
Why?
| | DNA Damage | 1 | 2019 | 437 | 0.120 |
Why?
| | Wolff-Parkinson-White Syndrome | 1 | 2016 | 19 | 0.120 |
Why?
| | Nanofibers | 1 | 2015 | 23 | 0.120 |
Why?
| | Chromosomes, Human, Pair 14 | 4 | 1996 | 23 | 0.120 |
Why?
| | Treatment Failure | 1 | 2017 | 360 | 0.120 |
Why?
| | Polyesters | 1 | 2015 | 75 | 0.110 |
Why?
| | Sex Factors | 3 | 2026 | 2105 | 0.110 |
Why?
| | Quality of Life | 3 | 2024 | 3204 | 0.110 |
Why?
| | Chromosomes | 1 | 1995 | 106 | 0.110 |
Why?
| | Cross-Sectional Studies | 4 | 2019 | 5904 | 0.110 |
Why?
| | Europe | 3 | 2025 | 418 | 0.110 |
Why?
| | Propanolamines | 2 | 2009 | 40 | 0.110 |
Why?
| | Genotyping Techniques | 2 | 2012 | 71 | 0.110 |
Why?
| | Spectrum Analysis | 1 | 2015 | 85 | 0.110 |
Why?
| | Cell Membrane | 1 | 2018 | 707 | 0.100 |
Why?
| | Logistic Models | 2 | 2017 | 2134 | 0.100 |
Why?
| | Heart Aneurysm | 1 | 1994 | 12 | 0.100 |
Why?
| | Molecular Sequence Data | 6 | 2014 | 2883 | 0.100 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 187 | 0.100 |
Why?
| | Polymerase Chain Reaction | 7 | 2008 | 1041 | 0.100 |
Why?
| | DNA, Mitochondrial | 3 | 2004 | 211 | 0.100 |
Why?
| | Genetics | 1 | 2013 | 23 | 0.100 |
Why?
| | Cell Culture Techniques | 1 | 2016 | 372 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 5 | 2025 | 3904 | 0.100 |
Why?
| | Autophagy | 1 | 2016 | 291 | 0.100 |
Why?
| | Accessory Atrioventricular Bundle | 1 | 2013 | 13 | 0.100 |
Why?
| | Cell Enlargement | 1 | 2013 | 8 | 0.100 |
Why?
| | Giant Cells | 1 | 2013 | 21 | 0.100 |
Why?
| | Catheter Ablation | 2 | 2014 | 355 | 0.100 |
Why?
| | Exercise | 1 | 2025 | 2198 | 0.100 |
Why?
| | Amino Acid Sequence | 3 | 2016 | 2129 | 0.100 |
Why?
| | Mice, Inbred C57BL | 3 | 2026 | 5983 | 0.100 |
Why?
| | Equipment Failure Analysis | 1 | 2013 | 124 | 0.090 |
Why?
| | Monitoring, Physiologic | 2 | 2021 | 288 | 0.090 |
Why?
| | Tachycardia, Supraventricular | 1 | 2013 | 49 | 0.090 |
Why?
| | Atrioventricular Block | 1 | 2013 | 44 | 0.090 |
Why?
| | Action Potentials | 1 | 2016 | 502 | 0.090 |
Why?
| | Actins | 2 | 2026 | 425 | 0.090 |
Why?
| | Heredity | 2 | 2026 | 13 | 0.090 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 928 | 0.090 |
Why?
| | Surface Properties | 1 | 2013 | 386 | 0.090 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2026 | 177 | 0.090 |
Why?
| | American Heart Association | 1 | 2013 | 358 | 0.090 |
Why?
| | Anti-Arrhythmia Agents | 4 | 2021 | 144 | 0.090 |
Why?
| | Electrophysiological Phenomena | 1 | 2012 | 59 | 0.090 |
Why?
| | Genome-Wide Association Study | 3 | 2026 | 1407 | 0.090 |
Why?
| | Nuclear Lamina | 2 | 2020 | 12 | 0.090 |
Why?
| | Penetrance | 1 | 2011 | 30 | 0.090 |
Why?
| | Kaplan-Meier Estimate | 4 | 2015 | 969 | 0.090 |
Why?
| | Survival Rate | 6 | 2021 | 2090 | 0.090 |
Why?
| | Equipment Design | 1 | 2013 | 525 | 0.090 |
Why?
| | Chromosome Disorders | 3 | 1997 | 47 | 0.080 |
Why?
| | Biomarkers | 2 | 2023 | 4295 | 0.080 |
Why?
| | Sex Chromosome Aberrations | 3 | 1997 | 69 | 0.080 |
Why?
| | Prospective Studies | 9 | 2023 | 8057 | 0.080 |
Why?
| | Graft Rejection | 2 | 2004 | 521 | 0.080 |
Why?
| | Disease Models, Animal | 5 | 2025 | 4560 | 0.080 |
Why?
| | Sensitivity and Specificity | 6 | 2015 | 1997 | 0.080 |
Why?
| | Chromosome Aberrations | 3 | 1997 | 166 | 0.080 |
Why?
| | Bundle-Branch Block | 2 | 2024 | 37 | 0.080 |
Why?
| | Collagen | 2 | 2026 | 457 | 0.080 |
Why?
| | Introns | 2 | 2025 | 255 | 0.080 |
Why?
| | Syndrome | 1 | 2011 | 381 | 0.080 |
Why?
| | Exons | 3 | 2025 | 363 | 0.080 |
Why?
| | Cell Division | 1 | 2012 | 756 | 0.080 |
Why?
| | Robotics | 1 | 2011 | 90 | 0.080 |
Why?
| | Practice Guidelines as Topic | 2 | 2015 | 1581 | 0.080 |
Why?
| | Diagnosis, Differential | 4 | 2020 | 1508 | 0.080 |
Why?
| | Sarcoidosis | 1 | 2012 | 163 | 0.080 |
Why?
| | Gene Frequency | 3 | 2017 | 487 | 0.080 |
Why?
| | Chromosomes, Human, Pair 3 | 3 | 2004 | 43 | 0.080 |
Why?
| | Genetic Counseling | 2 | 2009 | 80 | 0.080 |
Why?
| | Family | 2 | 2014 | 682 | 0.080 |
Why?
| | Sequence Deletion | 3 | 2014 | 190 | 0.070 |
Why?
| | Models, Biological | 3 | 2024 | 1764 | 0.070 |
Why?
| | Enterovirus | 3 | 1994 | 83 | 0.070 |
Why?
| | RNA | 3 | 2023 | 910 | 0.070 |
Why?
| | Rats, Wistar | 2 | 2024 | 450 | 0.070 |
Why?
| | Disease-Free Survival | 3 | 2015 | 767 | 0.070 |
Why?
| | Immunohistochemistry | 3 | 2018 | 1716 | 0.070 |
Why?
| | Signal Transduction | 4 | 2026 | 5216 | 0.070 |
Why?
| | Recovery of Function | 2 | 2026 | 716 | 0.070 |
Why?
| | Cardiomyopathy, Restrictive | 4 | 1999 | 11 | 0.070 |
Why?
| | Global Health | 2 | 2014 | 403 | 0.070 |
Why?
| | Cardiac Surgical Procedures | 1 | 2014 | 610 | 0.070 |
Why?
| | Nanoparticles | 1 | 2014 | 517 | 0.070 |
Why?
| | Organic Cation Transport Proteins | 1 | 2008 | 25 | 0.070 |
Why?
| | United States | 8 | 2021 | 16098 | 0.070 |
Why?
| | Age Factors | 3 | 2026 | 3342 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2026 | 2158 | 0.070 |
Why?
| | Amiodarone | 4 | 2011 | 31 | 0.070 |
Why?
| | Carnitine | 1 | 2008 | 91 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2025 | 2953 | 0.060 |
Why?
| | Endothelin-1 | 1 | 2009 | 181 | 0.060 |
Why?
| | Organ Specificity | 2 | 2026 | 309 | 0.060 |
Why?
| | Consensus | 2 | 2019 | 477 | 0.060 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 1997 | 80 | 0.060 |
Why?
| | Retinitis Pigmentosa | 1 | 2006 | 20 | 0.060 |
Why?
| | Endocardium | 3 | 1999 | 31 | 0.060 |
Why?
| | Endocardial Cushions | 1 | 2025 | 7 | 0.060 |
Why?
| | Smad3 Protein | 1 | 2026 | 42 | 0.060 |
Why?
| | Smad2 Protein | 1 | 2026 | 37 | 0.060 |
Why?
| | Triiodothyronine | 1 | 2026 | 54 | 0.060 |
Why?
| | Lysosomal-Associated Membrane Protein 2 | 3 | 2014 | 32 | 0.060 |
Why?
| | Myopia | 1 | 2006 | 59 | 0.060 |
Why?
| | Gene Expression | 3 | 2008 | 1476 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2026 | 3124 | 0.060 |
Why?
| | Thyroid Hormones | 1 | 2026 | 68 | 0.060 |
Why?
| | Facies | 1 | 2025 | 22 | 0.060 |
Why?
| | Fibronectins | 1 | 2026 | 136 | 0.060 |
Why?
| | Molecular Epidemiology | 1 | 2005 | 73 | 0.060 |
Why?
| | Societies, Medical | 2 | 2025 | 899 | 0.050 |
Why?
| | Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2025 | 38 | 0.050 |
Why?
| | Systole | 1 | 2025 | 181 | 0.050 |
Why?
| | Conserved Sequence | 1 | 2005 | 244 | 0.050 |
Why?
| | Autoimmune Diseases | 3 | 2001 | 468 | 0.050 |
Why?
| | Child, Preschool | 6 | 2017 | 11853 | 0.050 |
Why?
| | Prenatal Diagnosis | 1 | 2006 | 196 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2018 | 3623 | 0.050 |
Why?
| | Methylation | 1 | 2025 | 242 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2025 | 177 | 0.050 |
Why?
| | NIH 3T3 Cells | 2 | 2015 | 146 | 0.050 |
Why?
| | Homozygote | 2 | 2015 | 199 | 0.050 |
Why?
| | Osteoblasts | 1 | 2025 | 145 | 0.050 |
Why?
| | Potassium Channels | 1 | 2025 | 147 | 0.050 |
Why?
| | Hemodynamics | 9 | 1992 | 1118 | 0.050 |
Why?
| | Cell Shape | 2 | 2015 | 56 | 0.050 |
Why?
| | Virus Diseases | 3 | 1998 | 216 | 0.050 |
Why?
| | Aortic Diseases | 1 | 2025 | 125 | 0.050 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2024 | 35 | 0.050 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2023 | 32 | 0.050 |
Why?
| | Primary Prevention | 2 | 2016 | 219 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2026 | 442 | 0.050 |
Why?
| | Amino Acid Substitution | 1 | 2004 | 302 | 0.050 |
Why?
| | Haplotypes | 3 | 2013 | 499 | 0.050 |
Why?
| | Transplantation, Homologous | 1 | 2004 | 418 | 0.050 |
Why?
| | Transforming Growth Factors | 1 | 2023 | 3 | 0.050 |
Why?
| | Aged, 80 and over | 4 | 2013 | 8333 | 0.050 |
Why?
| | Cataract | 1 | 2006 | 238 | 0.050 |
Why?
| | Clinical Trials as Topic | 2 | 2004 | 1061 | 0.050 |
Why?
| | Calcinosis | 1 | 2025 | 234 | 0.050 |
Why?
| | Codon, Nonsense | 1 | 2023 | 44 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 14 | 1 | 2022 | 7 | 0.050 |
Why?
| | Oxidative Phosphorylation | 1 | 2023 | 209 | 0.050 |
Why?
| | Antigens, CD | 2 | 2017 | 558 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 116 | 0.050 |
Why?
| | Dogs | 1 | 2023 | 458 | 0.050 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2022 | 109 | 0.040 |
Why?
| | Recurrence | 1 | 2025 | 1138 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2024 | 231 | 0.040 |
Why?
| | Antigens, Neoplasm | 1 | 2023 | 271 | 0.040 |
Why?
| | Glycolysis | 1 | 2023 | 340 | 0.040 |
Why?
| | Pregnancy | 3 | 2022 | 7202 | 0.040 |
Why?
| | Optical Tweezers | 1 | 2021 | 21 | 0.040 |
Why?
| | Genetic Background | 1 | 2021 | 16 | 0.040 |
Why?
| | Metoprolol | 2 | 1999 | 26 | 0.040 |
Why?
| | Mass Screening | 1 | 2010 | 1360 | 0.040 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 2187 | 0.040 |
Why?
| | Apoptosis | 2 | 2021 | 2440 | 0.040 |
Why?
| | Nanotubes | 1 | 2021 | 46 | 0.040 |
Why?
| | Pyrroles | 1 | 2022 | 220 | 0.040 |
Why?
| | Cell Line | 2 | 2019 | 2823 | 0.040 |
Why?
| | Base Sequence | 5 | 2014 | 2170 | 0.040 |
Why?
| | RNA, Messenger | 3 | 2020 | 2803 | 0.040 |
Why?
| | Ephrin-B2 | 1 | 2021 | 45 | 0.040 |
Why?
| | Electric Conductivity | 1 | 2020 | 85 | 0.040 |
Why?
| | Gadolinium | 1 | 2021 | 84 | 0.040 |
Why?
| | Transfection | 2 | 2017 | 926 | 0.040 |
Why?
| | Ferric Compounds | 1 | 2020 | 54 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 2023 | 474 | 0.040 |
Why?
| | HeLa Cells | 2 | 2015 | 632 | 0.040 |
Why?
| | Denmark | 1 | 2019 | 51 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 2 | 2018 | 365 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2023 | 1067 | 0.040 |
Why?
| | RNA, Viral | 2 | 1994 | 692 | 0.040 |
Why?
| | Computational Biology | 2 | 2015 | 669 | 0.040 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2022 | 627 | 0.040 |
Why?
| | Maleimides | 1 | 2019 | 21 | 0.040 |
Why?
| | Brazil | 1 | 2019 | 179 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 193 | 0.040 |
Why?
| | Cell Plasticity | 1 | 2019 | 37 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2020 | 305 | 0.040 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2019 | 39 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 886 | 0.040 |
Why?
| | Carbazoles | 1 | 1999 | 53 | 0.040 |
Why?
| | E2F Transcription Factors | 1 | 2019 | 65 | 0.040 |
Why?
| | CpG Islands | 1 | 2019 | 163 | 0.040 |
Why?
| | Regeneration | 1 | 2020 | 197 | 0.040 |
Why?
| | Heterochromatin | 1 | 2019 | 66 | 0.030 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2018 | 18 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2020 | 500 | 0.030 |
Why?
| | Canada | 1 | 2019 | 431 | 0.030 |
Why?
| | Glucose | 1 | 2023 | 1048 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1480 | 0.030 |
Why?
| | Alginates | 1 | 2018 | 60 | 0.030 |
Why?
| | Intercellular Junctions | 1 | 2017 | 35 | 0.030 |
Why?
| | Infant | 4 | 2020 | 10077 | 0.030 |
Why?
| | Proportional Hazards Models | 2 | 2013 | 1327 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2021 | 3413 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 934 | 0.030 |
Why?
| | Ultrasonography | 2 | 1999 | 785 | 0.030 |
Why?
| | beta Catenin | 1 | 2019 | 254 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2018 | 264 | 0.030 |
Why?
| | Netherlands | 1 | 2017 | 84 | 0.030 |
Why?
| | Multilevel Analysis | 1 | 2017 | 36 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2018 | 563 | 0.030 |
Why?
| | Aorta | 1 | 2000 | 440 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 2 | 2018 | 981 | 0.030 |
Why?
| | Cell Movement | 1 | 2021 | 959 | 0.030 |
Why?
| | Membrane Potentials | 1 | 2017 | 278 | 0.030 |
Why?
| | Incidence | 3 | 2011 | 2923 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 527 | 0.030 |
Why?
| | Molecular Dynamics Simulation | 1 | 2018 | 265 | 0.030 |
Why?
| | Lod Score | 1 | 1995 | 62 | 0.030 |
Why?
| | Gene Editing | 1 | 2017 | 89 | 0.030 |
Why?
| | Sodium | 1 | 2017 | 198 | 0.030 |
Why?
| | Genes, Recessive | 1 | 1995 | 78 | 0.030 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2015 | 196 | 0.030 |
Why?
| | CRISPR-Cas Systems | 1 | 2017 | 166 | 0.030 |
Why?
| | Indoles | 1 | 2019 | 507 | 0.030 |
Why?
| | Cadherins | 1 | 2017 | 200 | 0.030 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 1995 | 149 | 0.030 |
Why?
| | Genes, Immunoglobulin | 1 | 1994 | 29 | 0.030 |
Why?
| | Enterovirus Infections | 2 | 1994 | 173 | 0.030 |
Why?
| | Viscosity | 1 | 2015 | 92 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2015 | 105 | 0.030 |
Why?
| | Mutagenesis | 1 | 2015 | 194 | 0.030 |
Why?
| | Cytochalasins | 1 | 2014 | 3 | 0.030 |
Why?
| | Single-Cell Analysis | 1 | 2017 | 362 | 0.030 |
Why?
| | Hospitalization | 1 | 2025 | 2460 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 741 | 0.030 |
Why?
| | Major Histocompatibility Complex | 1 | 1994 | 233 | 0.030 |
Why?
| | Gene Expression Regulation, Viral | 1 | 1994 | 93 | 0.020 |
Why?
| | Tubulin | 1 | 2015 | 146 | 0.020 |
Why?
| | Cardiac Myosins | 1 | 2013 | 37 | 0.020 |
Why?
| | Translocation, Genetic | 1 | 1994 | 119 | 0.020 |
Why?
| | Morbidity | 1 | 2014 | 322 | 0.020 |
Why?
| | Body Temperature | 1 | 2014 | 227 | 0.020 |
Why?
| | Ventricular Fibrillation | 1 | 2013 | 64 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 1994 | 208 | 0.020 |
Why?
| | Cause of Death | 1 | 2015 | 470 | 0.020 |
Why?
| | Turner Syndrome | 1 | 1994 | 65 | 0.020 |
Why?
| | Electrophysiology | 1 | 2013 | 218 | 0.020 |
Why?
| | Formaldehyde | 1 | 2013 | 65 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2014 | 1048 | 0.020 |
Why?
| | Skin | 1 | 2017 | 753 | 0.020 |
Why?
| | Cell Survival | 1 | 2015 | 1100 | 0.020 |
Why?
| | Lymphatic Diseases | 1 | 2012 | 21 | 0.020 |
Why?
| | Mediastinal Diseases | 1 | 2012 | 10 | 0.020 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2930 | 0.020 |
Why?
| | Cattle | 1 | 2014 | 946 | 0.020 |
Why?
| | Pacemaker, Artificial | 1 | 2013 | 128 | 0.020 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1992 | 58 | 0.020 |
Why?
| | Patient Selection | 1 | 2015 | 738 | 0.020 |
Why?
| | Blood Pressure | 2 | 2016 | 1779 | 0.020 |
Why?
| | Antibody Formation | 1 | 1992 | 288 | 0.020 |
Why?
| | Immune System | 1 | 1992 | 180 | 0.020 |
Why?
| | Observer Variation | 1 | 2011 | 357 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2013 | 728 | 0.020 |
Why?
| | Drug Therapy, Combination | 2 | 2004 | 1044 | 0.020 |
Why?
| | Endothelin-Converting Enzymes | 1 | 2009 | 10 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2010 | 251 | 0.020 |
Why?
| | Aspartic Acid Endopeptidases | 1 | 2009 | 32 | 0.020 |
Why?
| | Metalloendopeptidases | 1 | 2009 | 63 | 0.020 |
Why?
| | Endothelins | 1 | 2009 | 61 | 0.020 |
Why?
| | Solute Carrier Family 22 Member 5 | 1 | 2008 | 7 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2016 | 3542 | 0.020 |
Why?
| | Autoimmunity | 1 | 1994 | 933 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2009 | 253 | 0.020 |
Why?
| | Cricetulus | 1 | 2008 | 118 | 0.020 |
Why?
| | Death, Sudden | 1 | 1987 | 26 | 0.020 |
Why?
| | CHO Cells | 1 | 2008 | 169 | 0.020 |
Why?
| | Calcium Channel Blockers | 1 | 1988 | 166 | 0.020 |
Why?
| | Cricetinae | 1 | 2008 | 305 | 0.020 |
Why?
| | Amyloidosis | 1 | 1987 | 44 | 0.020 |
Why?
| | Genetic Carrier Screening | 1 | 2007 | 32 | 0.020 |
Why?
| | Frameshift Mutation | 1 | 2006 | 31 | 0.020 |
Why?
| | Pigment Epithelium of Eye | 1 | 2006 | 36 | 0.020 |
Why?
| | Electroretinography | 1 | 2006 | 50 | 0.020 |
Why?
| | Models, Genetic | 1 | 2009 | 524 | 0.010 |
Why?
| | Visual Fields | 1 | 2006 | 116 | 0.010 |
Why?
| | Algorithms | 1 | 2013 | 1845 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2007 | 408 | 0.010 |
Why?
| | Fluorescein Angiography | 1 | 2006 | 190 | 0.010 |
Why?
| | Antimetabolites | 1 | 2004 | 21 | 0.010 |
Why?
| | Growth Inhibitors | 1 | 2004 | 39 | 0.010 |
Why?
| | Coxsackievirus Infections | 1 | 1984 | 14 | 0.010 |
Why?
| | Azathioprine | 1 | 2004 | 44 | 0.010 |
Why?
| | Calcineurin Inhibitors | 1 | 2004 | 69 | 0.010 |
Why?
| | Terminology as Topic | 2 | 1999 | 257 | 0.010 |
Why?
| | Everolimus | 1 | 2004 | 112 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2005 | 397 | 0.010 |
Why?
| | Mycophenolic Acid | 1 | 2004 | 120 | 0.010 |
Why?
| | Chromatography, Liquid | 1 | 2005 | 450 | 0.010 |
Why?
| | Cyclosporine | 1 | 2004 | 256 | 0.010 |
Why?
| | Tacrolimus | 1 | 2004 | 196 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 855 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4553 | 0.010 |
Why?
| | Captopril | 1 | 1983 | 11 | 0.010 |
Why?
| | Sirolimus | 1 | 2004 | 280 | 0.010 |
Why?
| | Comorbidity | 1 | 2008 | 1661 | 0.010 |
Why?
| | Proline | 1 | 1983 | 82 | 0.010 |
Why?
| | Probability | 1 | 2003 | 307 | 0.010 |
Why?
| | Administration, Oral | 1 | 2004 | 866 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 428 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 2004 | 484 | 0.010 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2004 | 454 | 0.010 |
Why?
| | Risk | 1 | 2003 | 919 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 1992 | 1957 | 0.010 |
Why?
| | Enterovirus B, Human | 2 | 1993 | 25 | 0.010 |
Why?
| | Chronic Disease | 1 | 1985 | 1808 | 0.010 |
Why?
| | Echocardiography, Doppler | 1 | 1999 | 115 | 0.010 |
Why?
| | World Health Organization | 1 | 1998 | 104 | 0.010 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 1999 | 229 | 0.010 |
Why?
| | Survival Analysis | 2 | 1991 | 1374 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 1999 | 608 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 1999 | 718 | 0.010 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1995 | 92 | 0.010 |
Why?
| | Receptors, Interleukin | 1 | 1994 | 43 | 0.010 |
Why?
| | Gene Amplification | 1 | 1994 | 118 | 0.010 |
Why?
| | Receptors, Fc | 1 | 1994 | 54 | 0.010 |
Why?
| | Fathers | 1 | 1994 | 53 | 0.010 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1993 | 157 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1993 | 164 | 0.010 |
Why?
| | Virology | 1 | 1993 | 36 | 0.010 |
Why?
| | Interleukins | 1 | 1994 | 248 | 0.010 |
Why?
| | Genome, Viral | 1 | 1994 | 214 | 0.010 |
Why?
| | Pindolol | 1 | 1992 | 2 | 0.010 |
Why?
| | Iodocyanopindolol | 1 | 1992 | 2 | 0.010 |
Why?
| | Neuropeptide Y | 1 | 1992 | 9 | 0.010 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 1992 | 19 | 0.010 |
Why?
| | Adenylyl Cyclases | 1 | 1992 | 60 | 0.010 |
Why?
| | Species Specificity | 1 | 1993 | 546 | 0.010 |
Why?
| | Catecholamines | 1 | 1992 | 88 | 0.010 |
Why?
| | Isoproterenol | 1 | 1992 | 96 | 0.010 |
Why?
| | Autoantigens | 1 | 1994 | 427 | 0.010 |
Why?
| | Complement System Proteins | 1 | 1994 | 314 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 1996 | 1246 | 0.010 |
Why?
| | DNA, Viral | 1 | 1993 | 356 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1994 | 673 | 0.010 |
Why?
| | Felodipine | 1 | 1988 | 3 | 0.000 |
Why?
| | Nitrendipine | 1 | 1988 | 12 | 0.000 |
Why?
| | Nisoldipine | 1 | 1988 | 7 | 0.000 |
Why?
| | Nicardipine | 1 | 1988 | 6 | 0.000 |
Why?
| | Diltiazem | 1 | 1988 | 17 | 0.000 |
Why?
| | Nifedipine | 1 | 1988 | 27 | 0.000 |
Why?
| | Transcription, Genetic | 1 | 1995 | 1454 | 0.000 |
Why?
| | Verapamil | 1 | 1988 | 37 | 0.000 |
Why?
| | Statistics as Topic | 1 | 1989 | 283 | 0.000 |
Why?
| | Infant, Newborn | 1 | 1999 | 6447 | 0.000 |
Why?
| | Autoantibodies | 1 | 1994 | 1509 | 0.000 |
Why?
| | Cardiomyopathy, Alcoholic | 1 | 1985 | 1 | 0.000 |
Why?
| | Physical Exertion | 1 | 1986 | 205 | 0.000 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 1985 | 85 | 0.000 |
Why?
| | Heart Septal Defects | 1 | 1984 | 12 | 0.000 |
Why?
| | Cardiac Output | 1 | 1984 | 179 | 0.000 |
Why?
| | Cardiac Catheterization | 1 | 1987 | 558 | 0.000 |
Why?
| | Vascular Resistance | 1 | 1984 | 370 | 0.000 |
Why?
| | Coronary Disease | 1 | 1984 | 381 | 0.000 |
Why?
| | Ethanol | 1 | 1985 | 631 | 0.000 |
Why?
| | Antibodies, Viral | 1 | 1984 | 674 | 0.000 |
Why?
| | Hypertension | 1 | 1985 | 1273 | 0.000 |
Why?
|
|
Mestroni's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|